Several KEAP1 substrates have been identified, including NRF2, p62, and MGM3, which are associated with proteasome‐dependent degradation.[21, 22] Furthermore, KEAP1 mutations, deletions, or epigenetic silencing are frequently observed in various cancers.[23, 24, 25, 26] Recently, systematic sequencing studies have also revealed that the loss‐of‐function somatic KEAP1 mutations are most frequently found in lung carcinoma (11%) and HCC (8%),[23, 27, 28] indicating a tumor‐suppressive role of this protein in these cancers. Here, KEAP1 is linked to neoplasm.